Bayer (FRA:BAYN) has been given a €86.00 ($100.00) price target by equities research analysts at Berenberg Bank in a note issued to investors on Tuesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the healthcare company’s stock. Berenberg Bank’s price objective would suggest a potential upside of 15.22% from the stock’s previous close.

Several other equities research analysts have also recently commented on BAYN. Goldman Sachs Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Monday, November 18th. Baader Bank set a €123.00 ($143.02) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Thursday, December 5th. Independent Research set a €61.00 ($70.93) target price on Bayer and gave the stock a “sell” rating in a report on Thursday, October 31st. Morgan Stanley set a €86.00 ($100.00) price target on Bayer and gave the company a “buy” rating in a research note on Monday, January 6th. Finally, Kepler Capital Markets set a €73.00 ($84.88) price target on Bayer and gave the company a “neutral” rating in a report on Thursday, January 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of €79.65 ($92.61).

Shares of BAYN stock traded down €0.09 ($0.10) during trading hours on Tuesday, hitting €74.64 ($86.79). 1,017,359 shares of the company were exchanged. The business has a 50 day moving average of €71.39 and a two-hundred day moving average of €65.79. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: How Do I Invest in Dividend Stocks

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.